{"id":"1-optive","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=1. Optive","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:59:21.034922+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:59:26.998715+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=1. Optive","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:59:27.200847+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL409372/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:59:28.821922+00:00"}},"_dailymed":null,"_scrapedAt":"2026-03-28T00:24:21.204Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:59:30.400785+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT04125134","phase":"PHASE4","title":"Predicting the Success of Dry Eye Disease Interventions Using Clinical Tests","status":"TERMINATED","sponsor":"Tufts Medical Center","startDate":"2019-10-03","conditions":"Dry Eye","enrollment":36},{"nctId":"NCT06439394","phase":"","title":"An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-06-17","conditions":"Dry Eye","enrollment":52},{"nctId":"NCT06443775","phase":"","title":"An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-06-17","conditions":"Dry Eye","enrollment":47},{"nctId":"NCT01013077","phase":"NA","title":"The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability","status":"COMPLETED","sponsor":"Southern California College of Optometry at Marshall B. Ketchum University","startDate":"2009-11","conditions":"Dry Eye Syndrome","enrollment":20},{"nctId":"NCT06375343","phase":"PHASE1","title":"Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®","status":"NOT_YET_RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2026-01-30","conditions":"Dry Eye Disease, Dry Eye Sensation, Ocular Surface Disease","enrollment":32},{"nctId":"NCT05705518","phase":"PHASE4","title":"Artificial Tears, Tear Lipids and Tear Film Dynamics","status":"COMPLETED","sponsor":"University of California, Berkeley","startDate":"2023-01-30","conditions":"Dry Eye","enrollment":81},{"nctId":"NCT06221345","phase":"PHASE4","title":"Hyaluronic Acid-containing Artificial Tears in Post-cataract Surgery Dry Eye Disease","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-12-07","conditions":"Dry Eye Disease, Cataract","enrollment":70},{"nctId":"NCT03380624","phase":"PHASE4","title":"Tear Lipid Layer Thickness With Emollient Eye Drops","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2017-03-01","conditions":"Dry Eye Syndromes","enrollment":21},{"nctId":"NCT02871440","phase":"PHASE3","title":"A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye","status":"COMPLETED","sponsor":"The University of New South Wales","startDate":"2016-09-19","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT02986750","phase":"PHASE4","title":"Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2016-02-13","conditions":"Dry Eye Syndromes","enrollment":120},{"nctId":"NCT03208673","phase":"NA","title":"Optive Brand For Day And Night Dry Eye Management","status":"COMPLETED","sponsor":"Allergan","startDate":"2017-07-03","conditions":"Dry Eye","enrollment":35},{"nctId":"NCT02776670","phase":"NA","title":"Clinical Outcomes Following Treatment With SYSTANE® BALANCE","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2016-07-29","conditions":"Dry Eye","enrollment":308},{"nctId":"NCT02117687","phase":"PHASE4","title":"A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-05-14","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca","enrollment":80},{"nctId":"NCT02280473","phase":"PHASE3","title":"A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-11-13","conditions":"Dry Eye Syndromes","enrollment":188},{"nctId":"NCT01459588","phase":"PHASE3","title":"Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-10-01","conditions":"Dry Eye Syndromes","enrollment":315},{"nctId":"NCT02818816","phase":"PHASE4","title":"Preoperative Brimonidine on IOP of Patients Undergoing RALP","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2016-02-29","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT03517748","phase":"NA","title":"Evaluation of the Efficacy and Safety of DM05 Versus Optive™ on the Treatment of Moderate to Severe Ocular Dryness","status":"COMPLETED","sponsor":"Horus Pharma","startDate":"2016-12-01","conditions":"Dry Eye","enrollment":80},{"nctId":"NCT02553772","phase":"PHASE3","title":"A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-01-06","conditions":"Dry Eye Syndromes","enrollment":242},{"nctId":"NCT03140111","phase":"NA","title":"LAMELLEYE for the Treatment of Dry Eye Symptoms in pSS Patients","status":"UNKNOWN","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2017-10-16","conditions":"Dry Eye Syndromes, Primary Sjögren Syndrome","enrollment":12},{"nctId":"NCT03052140","phase":"NA","title":"Lamelleye vs Comparator for the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Glasgow Caledonian University","startDate":"2017-02-21","conditions":"Dry Eye Syndromes","enrollment":31},{"nctId":"NCT02806830","phase":"NA","title":"Ocular Discomfort Assessment After Intravitreal Injections","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2016-04","conditions":"Macular Degeneration, Diabetic Retinopathy, Retinal Artery Occlusion","enrollment":45},{"nctId":"NCT00812721","phase":"NA","title":"Tears Substitutions and Their Effects on Higher Order Aberrometery","status":"WITHDRAWN","sponsor":"Gina Rogers","startDate":"2009-01","conditions":"Dry Eye Syndrome","enrollment":""},{"nctId":"NCT02617095","phase":"NA","title":"Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome","status":"TERMINATED","sponsor":"Laboratoires Thea","startDate":"2015-02","conditions":"Dry Eye Syndrome","enrollment":64},{"nctId":"NCT01741987","phase":"NA","title":"Osmoprotective Containing Lubricants in Dysfunctional Tear Syndrome and Post Refractive Surgery Patients","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2008-10","conditions":"Dry Eye, Ametropia","enrollment":100},{"nctId":"NCT01664949","phase":"PHASE3","title":"A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-01","conditions":"Dry Eye Disease","enrollment":460},{"nctId":"NCT01863368","phase":"NA","title":"Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-09","conditions":"Dry Eye Syndrome","enrollment":105},{"nctId":"NCT00691197","phase":"PHASE2, PHASE3","title":"Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-03","conditions":"Ametropia","enrollment":246},{"nctId":"NCT00761202","phase":"PHASE4","title":"Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-08","conditions":"Dry Eye Syndromes","enrollment":50},{"nctId":"NCT01280110","phase":"PHASE4","title":"The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2011-03","conditions":"Dry Eye Syndromes","enrollment":44},{"nctId":"NCT01051804","phase":"PHASE4","title":"Evaluation of the Repeated Usage of Systane Ultra Eyedrop","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-11","conditions":"Dry Eye","enrollment":57},{"nctId":"NCT00673764","phase":"NA","title":"The Effect of Systane Ultra Lubricant Eye Drops (FID 112903) on Visual Performance","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-05","conditions":"Dry Eye","enrollment":48},{"nctId":"NCT00673959","phase":"NA","title":"Acute Comfort of Lubricant Eye Drop FID 111421","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-12","conditions":"Dry Eye","enrollment":20},{"nctId":"NCT00756093","phase":"NA","title":"Acute Comfort and Blurring Profile Evaluation of Marketed Lubricant Eye Drops","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-09","conditions":"Dry Eye","enrollment":20},{"nctId":"NCT00702377","phase":"NA","title":"Evaluation of SYSTANE Ultra Lubricant Eye Drops","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-06","conditions":"Dry Eye","enrollment":109},{"nctId":"NCT01368198","phase":"NA","title":"Evaluation of Extended Tear Film Break Up Time (TFBUT) With an Ocular Emulsion","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Dry Eye","enrollment":50},{"nctId":"NCT00673855","phase":"NA","title":"Acute Comfort of Lubricant Eye Drops FID 112903","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-05","conditions":"Dry Eye","enrollment":20},{"nctId":"NCT00568386","phase":"NA","title":"Acute Comfort and Blur of Systane and Optive","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-11","conditions":"Dry Eye","enrollment":40},{"nctId":"NCT00756678","phase":"PHASE4","title":"Efficacy and Acceptability of Two Lubricant Eye Drops","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-09","conditions":"Dry Eye Syndromes","enrollment":51},{"nctId":"NCT00938704","phase":"PHASE4","title":"Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-06","conditions":"Dry Eye Syndromes","enrollment":71},{"nctId":"NCT00987727","phase":"PHASE4","title":"Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-11","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca","enrollment":82},{"nctId":"NCT00570843","phase":"PHASE4","title":"Masked Comparison of a New PEG Based Artificial Tear and Optive for Comfort, Vision & Wear Time in Patients Wearing Contact Lenses","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-03","conditions":"Comfort, Vision and Wear Time","enrollment":50},{"nctId":"NCT00698724","phase":"PHASE4","title":"Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-06","conditions":"Cataracts","enrollment":200},{"nctId":"NCT00698945","phase":"PHASE4","title":"Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-06","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":40},{"nctId":"NCT00399061","phase":"PHASE4","title":"Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"2006-11","conditions":"Dry Eye","enrollment":55},{"nctId":"NCT00469157","phase":"PHASE4","title":"Refractive Surgery and Optive Compatibility Study","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"2007-05","conditions":"Dry Eye Syndromes","enrollment":92},{"nctId":"NCT00469573","phase":"PHASE4","title":"Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"2007-05","conditions":"Dry Eye","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL409372"},"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"1. Optive","genericName":"1. Optive","companyName":"Innovative Medical","companyId":"innovative-medical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:59:30.400785+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}